Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinsonâ€™s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.

Employees

674

Sector

Pharmaceuticals

Calendar

02-23 - Q4 2025 Earnings Release

More about the company

Quotes

Date	Price	Change	Volume
13/02/26	50.84 $	+1.99%	738,653
12/02/26	49.85 $	-2.90%	675,941
11/02/26	51.34 $	+0.31%	656,694
10/02/26	51.18 $	-0.23%	495,044
09/02/26	51.30 $	-0.68%	654,421

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

50.84USD

Average target price

61.33USD

Spread / Average Target

+20.64%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 21:00:00 13/02/2026 GMT			5-day change	1st Jan Change
50.84 ^USD	+1.99%		-1.57%	+2.29%

02-04	India's Lupin Launches Seizure Drug Bioequivalent to Supernus Pharmaceuticals' Trokendi XR	MT
02-04	Lupin Limited Launches Topiram Extended-Release Capsules in the United States	CI

Capitalization	2.92B 2.46B 2.24B 2.14B 3.97B 264B 4.13B 26.06B 10.34B 128B 10.93B 10.71B 446B	P/E ratio 2025 *	-71.9x	P/E ratio 2026 *	54.4x
Enterprise value	2.92B 2.46B 2.24B 2.14B 3.97B 264B 4.13B 26.06B 10.34B 128B 10.93B 10.71B 446B	EV / Sales 2025 *	4.15x	EV / Sales 2026 *	3.4x
Free-Float	94.99%	Yield 2025 *	-	Yield 2026 *	-

02-04	India's Lupin Launches Seizure Drug Bioequivalent to Supernus Pharmaceuticals' Trokendi XR	MT
02-04	Lupin Limited Launches Topiram Extended-Release Capsules in the United States	CI
01-07	Biopharma Sector Enters 2026 With Clearer Outlook, Key Catalysts, BofA Says	MT
12-08	Supernus Pharmaceuticals, Inc. Presents at BofA Securities CNS Therapeutics Virtual Conference 2025, Dec-08-2025 10:45 AM
11-05	Supernus Pharmaceuticals, Inc., Q3 2025 Earnings Call, Nov 04, 2025
11-04	Supernus Pharma Q3 revenue rises, partly helped by Sage acquisition	RE
11-04	Supernus Pharmaceuticals, Inc. Raises Earnings Guidance for the Year 2025	CI
11-04	Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
29/10/25	BofA Securities Initiates Supernus Pharmaceuticals at Buy With $65 Price Target	MT
10/10/25	Supernus Pharmaceuticals Insider Sold Shares Worth $3,029,336, According to a Recent SEC Filing	MT
09/10/25	Piper Sandler Upgrades Supernus Pharmaceuticals to Overweight From Neutral, Adjusts Price Target to $65 From $40	MT
02/10/25	Supernus Pharmaceuticals Insider Sold Shares Worth $1,931,116, According to a Recent SEC Filing	MT
24/09/25	Supernus Pharmaceuticals Insider Sold Shares Worth $1,393,899, According to a Recent SEC Filing	MT

01-07	Biopharma Sector Enters 2026 With Clearer Outlook, Key Catalysts, BofA Says	MT
29/10/25	BofA Securities Initiates Supernus Pharmaceuticals at Buy With $65 Price Target	MT
09/10/25	Piper Sandler Upgrades Supernus Pharmaceuticals to Overweight From Neutral, Adjusts Price Target to $65 From $40	MT
16/06/25	Wedbush Adjusts PT on SAGE Therapeutics to $8.50 From $6 on Heels of Announced Sale to Supernus; Maintains Neutral	MT
31/08/22	Piper Sandler Adjusts Price Target on Supernus Pharmaceuticals to $38 From $33, Reiterates Overweight Rating	MT

Supernus Pharmaceuticals, Inc. Share Price

Equities

SUPN

US8684591089

Pharmaceuticals

Valuation: Supernus Pharmaceuticals, Inc.

Chart: Supernus Pharmaceuticals, Inc.

Latest news: Supernus Pharmaceuticals, Inc.

Last Transcript: Supernus Pharmaceuticals, Inc.

Analysts' recommendations: Supernus Pharmaceuticals, Inc.

Press Releases: Supernus Pharmaceuticals, Inc.

News in other languages: Supernus Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Supernus Pharmaceuticals, Inc.

ETFs: Supernus Pharmaceuticals, Inc.

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

02-12	Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026	GL
12-03	Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference	GL
11-21	Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference	GL
11-04	Supernus Announces Third Quarter 2025 Financial Results	GL
05/08/25	Supernus: Q2 Earnings Snapshot	AQ

19/02/25	En direct des marchés : Sanofi vend Opella, Stellantis revient au diesel, Intel à la découpe
18/10/21	Newron erhält fünfte Tranche aus der Finanzierungsvereinbarung mit der Europäischen Investitionsbank (EIB)
18/10/21	Newron erhält fünfte Tranche aus der Finanzierungsvereinbarung mit der Europäischen Investitionsbank (EIB)
16/09/21	Newron berichtet über -2-
06/09/21	Newron erhält vierte Tranche aus der Finanzierungsvereinbarung mit der Europäischen Investitionsbank (EIB)

1 day	+1.99%
1 week	-1.57%
Current month	+5.56%
1 month	-1.19%
3 months	+14.40%
6 months	+19.23%
Current year	+2.29%

1 week	49.46	51.96
1 month	47.29	52.34
Current year	47.29	52.5
1 year	29.16	57.65
3 years	21.99	57.65
5 years	21.99	57.65
10 years	12.15	61.25

Manager	Title	Age	Since
Jack Khattar CEO	Chief Executive Officer	64	21/12/2005
Timothy Dec DFI	Director of Finance/CFO	67	22/08/2021
Kevin T. Anderson CMP	Compliance Officer	63	31/12/2011

Director	Title	Age	Since
Jack Khattar BRD	Director/Board Member	64	21/12/2005
Charles Newhall CHM	Chairman	80	09/08/2016
Frederick Hudson BRD	Director/Board Member	80	15/11/2010

Name		Varia. Jan 1.	Weight	AuM
HARTFORD MULTIFACTOR SMALL CAP ETF - USD		+8.10%	0.94%	30 M€
ROYCE QUANT SMALL-CAP QUALITY VALUE ETF - USD		+6.69%	0.38%	20 M€

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
SUPERNUS PHARMACEUTICALS, INC.	+1.99%	-1.57%	+28.61%	+28.90%	2.92B
MERCK KGAA	+1.91%	+5.23%	-6.68%	-31.51%	65.94B
HALOZYME THERAPEUTICS, INC.	+3.28%	-2.20%	+35.54%	+61.79%	9.34B
KYOWA KIRIN CO., LTD.	+4.73%	+12.01%	+27.75%	-10.75%	9.22B
SK BIOPHARMACEUTICALS CO., LTD.	-3.70%	+0.65%	-12.92%	+62.02%	5.93B
YUHAN CORPORATION	-0.55%	+3.82%	-13.38%	+118.43%	5.6B
INDIVIOR PHARMACEUTICALS, INC.	+2.43%	+0.64%	+243.06%	+47.11%	4.32B
MEZZION PHARMA CO.,LTD.	-2.42%	+4.53%	+414.34%	+1,003.26%	3.06B
BETTA PHARMACEUTICALS CO., LTD.	-2.59%	-2.84%	-11.81%	-28.58%	2.79B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-1.38%	-0.32%	+33.94%	+18.87%	2.47B
Average	+0.37%	+1.03%	+73.84%	+126.96%	11.16B
Weighted average by Cap.	+1.55%	+3.82%	+21.92%	+24.68%

	2025 *	2026 *
Net sales	702M 592M 540M 515M 956M 63.59B 994M 6.28B 2.49B 30.71B 2.63B 2.58B 107B	858M 723M 659M 629M 1.17B 77.68B 1.21B 7.67B 3.04B 37.51B 3.22B 3.15B 131B
Net income	-43.77M -36.88M -33.64M -32.12M -59.62M -3.96B -61.94M -391M -155M -1.91B -164M -161M -6.69B	53.22M 44.84M 40.9M 39.05M 72.48M 4.82B 75.31M 476M 189M 2.33B 200M 195M 8.14B
Net Debt	-	-